ASX All Ords Stock Orthocell Ltd (OCC) Soars on US Nerve Repair Product Sales
This morning, the Australian share market is back on form, with the All Ordinaries index up 0.5% to 8,823.2 points. Among the top performers is Orthocell Ltd (ASX: OCC), a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries.
At the time of writing, Orthocell Ltd’s shares are up almost 6% to $1.29, driven by the company’s announcement that it has recorded its first sales revenue from its flagship Remplir nerve repair product in the US market.
Remplir is a collagen wrap used in nerve repair surgery to improve regeneration of damaged nerves and patient outcomes. The company has highlighted that this ‘critical milestone’ in the commercialisation of Remplir in the US $1.6 billion US market follows the first surgical use of Remplir on 26 June and subsequent early surgical cases.
The achievement marks a transition from US FDA 510(k) clearance for Remplir to first sales revenue in just over three months. Surgical cases conducted to date have been sourced from Orthocell’s network of nerve repair specialist distributors. Furthermore, the company feels that in addition to building crucial surgical knowledge and experience with Remplir, the early surgical cases have been an important real-world validation of the order fulfilment process coordinated by on-the-ground logistics partner Uniphar and the associated customer invoicing requirements.
Orthocell Ltd’s CEO and managing director, Paul Anderson, was pleased with the news, stating that translating Remplir’s regulatory clearance in the US to first sales revenue in a little over three months is a testament to the hard work the company has done with its US roll-out plan.
The plan includes key internal hires in sales, marketing, and medical affairs, appointing specialist distributors, Australian manufacturing ramp-up, and working with on-the-ground US logistics partner Uniphar. Anderson emphasized that the early-stage day surgery cases are an ideal starting point and represent the perfect strategic platform to build from. This approach is similar to the market access model the company has successfully undertaken in Australia, where early surgery cases build familiarity and knowledge, leading to widespread adoption and therefore revenue growth.
The company expects to follow a similar path in the US, albeit on a far larger scale. Orthocell Ltd is confident that its efforts in the US are on track to drive growth in sales of Remplir during the second half of calendar 2025.
What’s Next for Orthocell Ltd?
With the company’s first sales revenue from Remplir in the US market, investors are eagerly awaiting the next stage of its growth journey. As the company continues to roll out its US plan, it will be interesting to see how Remplir performs in the market. With a strong track record of successful product launches and a growing presence in the US, Orthocell Ltd is well-positioned for future growth.
Conclusion
In conclusion, Orthocell Ltd’s announcement of its first sales revenue from Remplir in the US market is a significant milestone for the company. With its strong track record of successful product launches and a growing presence in the US, Orthocell Ltd is well-positioned for future growth. As investors, it’s essential to keep a close eye on the company’s progress and look out for future updates on its US roll-out plan.
